{"id":"W4205930483","doi":"10.1016/s2468-1253(21)00223-5","title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","year":2022,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":153,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"San Diego Digestive Diseases Research Center, School of Medicine, University of California, San Diego; Cilag; National Institute of Diabetes and Digestive and Kidney Diseases; Bristol-Myers Squibb; Samsung; Israel National Road Safety Authority; Vlaamse regering; Genentech; AstraZeneca; Allergan; Mylan; National Institutes of Health; Gilead Sciences; LEO Pharma; Novo Nordisk; Norgine; Fonds Wetenschappelijk Onderzoek; Mitsubishi Tanabe Pharma Corporation; Celltrion; Vifor Pharma; American Gastroenterological Association; Celgene; Pfizer; Biogen; Amgen; Eli Lilly and Company","keywords":"Therapeutic drug monitoring; Inflammatory bowel disease; Rheumatoid arthritis; Certolizumab pegol; Pharmacogenetics; Drug; Disease monitoring; Inflammatory Bowel Diseases; Clinical trial; Inflammatory arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02572975,0.001007194,0.004818786,0.001632027,0.000660253,0.00560504,0.002109379,0.007134782,0.005911612],"category_scores_gemma":[0.03307863,0.0005009245,0.001796547,0.001836784,0.003313793,0.0092393,0.001911556,0.007599224,0.002136935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003592051,"about_ca_system_score_gemma":0.005765233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002733225,"about_ca_topic_score_gemma":0.004623642,"domain_scores_codex":[0.9909992,0.004119719,0.001256237,0.0006777243,0.002399137,0.0005479314],"domain_scores_gemma":[0.9312599,0.0464716,0.005624069,0.001412895,0.01144285,0.003788706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001866377,0.0002292388,0.004228976,0.005307528,0.0005235097,0.0003476082,0.0001659707,0.001548625,0.001969756,0.0253325,0.1406475,0.8178325],"study_design_scores_gemma":[0.001116042,0.001384439,0.01297538,0.01294882,0.001061813,0.002381698,0.001076014,0.004256605,0.001029797,0.1078688,0.8536548,0.0002457394],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008110722,0.8275565,0.001177171,0.1658964,0.002344194,0.000007821644,0.0001720865,0.00005636581,0.001978432],"genre_scores_gemma":[0.0335575,0.8803128,0.004555384,0.05415536,0.02575928,0.00005594561,0.0003266145,0.00004914761,0.00122801],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02572975,"threshold_uncertainty_score":0.1360735,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008345255838129437,"score_gpt":0.2347150561786161,"score_spread":0.2263698003404866,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}